File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Deleted in Liver Cancer 1 (DLC1) is a negative regulator of metastasis and deregulated by kinase phosphorylation in hepatocellular carcinoma

TitleDeleted in Liver Cancer 1 (DLC1) is a negative regulator of metastasis and deregulated by kinase phosphorylation in hepatocellular carcinoma
Authors
Issue Date2010
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/
Citation
The 101st Annual Meeting of the American Association for Cancer Research (AACR), Washington DC., 17-21 April 2010. In Cancer Research, 2010, v. 70 n. 8 suppl., abstract no. 5003 How to Cite?
AbstractDeleted in liver cancer 1 (DLC1), which encodes a Rho GTPase activity protein (RhoGAP), is a bona fide tumor suppressor not only in hepatocellular carcinoma, but in a wide spectrum of human cancers. Underexpression of DLC1 is commonly found in human cancers and has been attributed to genomic deletion and epigenetic silencing. Recently, mutation of DLC1 identified from cancer patients is shown to inactivate its RhoGAP activity. However, the regulatory mechanism of the tumor suppressive activities of DLC1 is unclear. Recent study about the regulation of activity and compartmentalization of DLC1 by protein kinases has provided the first evidence that DLC1 activity could be regulated by post-translational modification. Moreover, identification of rat homolog of DLC1, p122RhoGAP, as the substrate of Akt has provided insight into the potential regulatory pathway of DLC1. However, the functional significance Akt phosphorylation in p122RhoGAP and its relevance in human DLC1 have not been investigated. In this study, we aimed to elucidate the molecular mechanism by which Akt phosphorylates DLC1 and the functional impact of this phosphorylation on DLC1 activities. In this study, we have shown that Akt interacts with the C-terminus of DLC1 and only Akt with intact kinase activity can interact and phosphorylate DLC1. Although this newly identified residue is distinct from the reported Akt phosphorylated residue in rat p122RhoGAP, it is well conserved in DLC family. Indeed, another family member, DLC2 is also phosphorylated by Akt. This implicates a common regulatory mechanism of DLC family by Akt signaling pathway. To determine the functional significance of phosphorylation of DLC1 by Akt, site-directed mutagenesis is employed to create phosphomimetic and phosphodefective mutant of DLC1. In vitro functional assays have demonstrated that phosphomimetic DLC1 suppresses growth, colony formation and anchorage independent growth of transformed hepatoblasts. Moreover, using subcutaneous injection and orthotopic tumor implantation models, phosphomimetic DLC1 mutant loses its inhibitory activities in tumorigenesis and metastasis of transformed hepatoblasts in nude mice. In conclusion, our findings have identified a novel post-translational modification by which Akt phosphorylation functionally deregulates the tumor suppressive activities of DLC1. Herein we show that apart from underexpression and mutation of DLC1, the enhanced phosphorylation level of DLC1 could be an indicator of deregulated DLC1 in cancers with normal expression level of DLC1.
DescriptionSession - Cellular and Molecular Biology: no. 5003
Persistent Identifierhttp://hdl.handle.net/10722/104469
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorKo, FCF-
dc.contributor.authorChan, LK-
dc.contributor.authorTung, KK-
dc.contributor.authorNg, IOL-
dc.contributor.authorYam, JWP-
dc.date.accessioned2010-09-25T21:54:21Z-
dc.date.available2010-09-25T21:54:21Z-
dc.date.issued2010-
dc.identifier.citationThe 101st Annual Meeting of the American Association for Cancer Research (AACR), Washington DC., 17-21 April 2010. In Cancer Research, 2010, v. 70 n. 8 suppl., abstract no. 5003-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/104469-
dc.descriptionSession - Cellular and Molecular Biology: no. 5003-
dc.description.abstractDeleted in liver cancer 1 (DLC1), which encodes a Rho GTPase activity protein (RhoGAP), is a bona fide tumor suppressor not only in hepatocellular carcinoma, but in a wide spectrum of human cancers. Underexpression of DLC1 is commonly found in human cancers and has been attributed to genomic deletion and epigenetic silencing. Recently, mutation of DLC1 identified from cancer patients is shown to inactivate its RhoGAP activity. However, the regulatory mechanism of the tumor suppressive activities of DLC1 is unclear. Recent study about the regulation of activity and compartmentalization of DLC1 by protein kinases has provided the first evidence that DLC1 activity could be regulated by post-translational modification. Moreover, identification of rat homolog of DLC1, p122RhoGAP, as the substrate of Akt has provided insight into the potential regulatory pathway of DLC1. However, the functional significance Akt phosphorylation in p122RhoGAP and its relevance in human DLC1 have not been investigated. In this study, we aimed to elucidate the molecular mechanism by which Akt phosphorylates DLC1 and the functional impact of this phosphorylation on DLC1 activities. In this study, we have shown that Akt interacts with the C-terminus of DLC1 and only Akt with intact kinase activity can interact and phosphorylate DLC1. Although this newly identified residue is distinct from the reported Akt phosphorylated residue in rat p122RhoGAP, it is well conserved in DLC family. Indeed, another family member, DLC2 is also phosphorylated by Akt. This implicates a common regulatory mechanism of DLC family by Akt signaling pathway. To determine the functional significance of phosphorylation of DLC1 by Akt, site-directed mutagenesis is employed to create phosphomimetic and phosphodefective mutant of DLC1. In vitro functional assays have demonstrated that phosphomimetic DLC1 suppresses growth, colony formation and anchorage independent growth of transformed hepatoblasts. Moreover, using subcutaneous injection and orthotopic tumor implantation models, phosphomimetic DLC1 mutant loses its inhibitory activities in tumorigenesis and metastasis of transformed hepatoblasts in nude mice. In conclusion, our findings have identified a novel post-translational modification by which Akt phosphorylation functionally deregulates the tumor suppressive activities of DLC1. Herein we show that apart from underexpression and mutation of DLC1, the enhanced phosphorylation level of DLC1 could be an indicator of deregulated DLC1 in cancers with normal expression level of DLC1.-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/-
dc.relation.ispartofCancer Research-
dc.titleDeleted in Liver Cancer 1 (DLC1) is a negative regulator of metastasis and deregulated by kinase phosphorylation in hepatocellular carcinoma-
dc.typeConference_Paper-
dc.identifier.emailKo, FCF: frankieko@pathology.hku.hk, bokcf@hkucc.hku.hk-
dc.identifier.emailChan, LK: lokongchan@gmail.com-
dc.identifier.emailTung, KK: edmund@pathology.hku.hk-
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hk-
dc.identifier.emailYam, JWP: judyyam@pathology.hku.hk-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityYam, JWP=rp00468-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1158/1538-7445.AM10-5003-
dc.identifier.hkuros170190-
dc.identifier.volume70-
dc.identifier.issue8 suppl., abstract no. 5003-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats